Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 10, 2012, Pages 1845-1847

  Llinares Tello, Francisca ^a   De Salazar, José Rosas Gómez ^a   Gallego, Josémiguel Senabre ^a   Soler, Gregorio Santos ^a   Ramírez, Carlos Santos ^b   Heredia, Esteban Salas ^a   García, Juan Molina ^a  

^a Marina Baixa Hospital   (Spain)

^b Hospital Marina Salud   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; ANTIBODY DETECTION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; RHEUMATIC DISEASE; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED;

EID: 84867759354     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0050     Document Type: Letter

References (10)

1. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
2. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
3. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-52.
4. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;63:877-83.
5. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16.
6. Rosas J, Llinares-Tello F, Senabre JM, Santos-Soler G, Santos-Ramírez C, Salas E, et al. Evaluation of anti-TNF levels and anti-TNF antibodies in rheumatic diseases treated with infliximab and adalimumab. Preliminary results from a local registry. Arthritis Rheum 2011;63(Suppl):S2211.
7. Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010;32:232-6.
8. Méric JC, Mulleman D, Ducourau E, Lauféron F, Miow Lin DC, Watier H, et al. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 2011;33:411-6.
9. Bartelds GM, Krieckaert CL, Nurmohamed MT, Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. J Am Med Assoc 2011;305:1460-8.
10. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheuma toid arthritis. Arthritis Rheum 2006;54:711-5.